Today we have a sober look at the future of mRNA, a plot to bring CAR-T back to its founding ideals, and the downside of a billion-dollar buyout. Are we sure mRNA can disrupt the flu? The Covid-19 pandemic was a historic proving ground for mRNA technology,...
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...
A day after the FDA launched an investigation into rare cases of secondary blood cancer in patients who received CAR-T therapies, clinicians are calling it a small risk factor for an otherwise effective drug class. Regulators are tracking 20 reports of T-cell...
The FDA is investigating reports of new cancer developments in patients treated with CAR-T cell immunotherapies, specifically targeting BCMA or CD19. This probe, announced on a recent Tuesday, follows cases from clinical trials and postmarketing surveillance where...
The FDA has postponed its decision on approving Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy for multiple myeloma in earlier treatment lines. Originally expected by December 16, the decision’s delay is due to the FDA’s plan to convene a...
